Dyslipidemia is one of the major causes of atherosclerosis and cardiovascular disease, the second death cause in Taiwan. Lipid-lowering agent is an effective therapy to retard atherosclerosis progression and reduce cardiovascular disease. 2014 NICE Lipid guideline, 2013 ACC/AHA and 2015 ADA guidelines have no lipid goal and recommend high-intensity statin therapy for the high risk population.
　　In this debate, the efficacy and safety of high-intensity statin on the atherosclerosis along the cardiovascular continuum will be mentioned.